PALISADE BIO, INC. — Director's Dealing 2021

Apr 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Seneca Biopharma, Inc. (SNCA)
CIK: 0001357459
Period of Report: 2021-04-01

Reporting Person: Mazzo David J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-01	Restricted Stock Units	$	A	6000	Acquired		Common Stock (6000)	Direct

Footnotes

F1: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22.

F2: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.